Background
It is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1
U
and KIM-1
S
) concentrations were useful in predicting cisplatin-induced AKI in early stages.
Methods
We prospectively analysed 22 patients on cisplatin treatment. KIM-1
S
and KIM-1
U
concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT1], third [AT3] and fifth [AT5] day after treatment).
Results
KIM-1
U
concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1
U
concentrations of the same patients BT (P = 0.009) and to AT1-KIM-1
U
concentrations of the patients without AKI (P = 0.008). A receiver operating characteristic analysis revealed that AT1-KIM-1
U
concentrations may predict AKI with an 87.5% sensitivity and 93.3% specificity (area under the curve = 0.94). KIM-1
S
concentrations were not significantly changed between BT and AT periods.
Conclusions
KIM-1
U
concentrations may predict cisplatin-induced AKI in early stages with high sensitivity and specificity.
